Core Viewpoint - The company has announced the grant of reserved stock options as part of its 2025 stock option incentive plan, with a total of 300,000 shares to be granted on August 25, 2025, representing 0.44% of the company's total share capital [1][4]. Group 1: Stock Option Grant Details - The reserved stock option grant date is set for August 25, 2025 [1]. - A total of 300,000 stock options will be granted to 5 incentive objects, with an exercise price of 57.689 yuan per share [4][19]. - The stock options are part of the company's 2025 stock option incentive plan, which has been approved by the board and the shareholders [2][19]. Group 2: Approval and Compliance - The company has completed all necessary approval procedures and disclosed relevant information regarding the stock option incentive plan [2][3]. - The board and supervisory committee have verified the list of incentive objects and confirmed compliance with the conditions set forth in the incentive plan [6][16]. - The incentive plan adheres to the regulations of the Shanghai Stock Exchange and relevant laws [19]. Group 3: Performance Conditions - The stock options will have a waiting period of 12 to 24 months before they can be exercised [8][10]. - The performance assessment for the stock options will be based on the company's financial performance in the years 2025 and 2026, with specific targets for revenue and net profit [10][11]. - If the performance targets are not met, the stock options will be canceled and not carried over to future years [12][13]. Group 4: Financial Impact and Accounting - The company will recognize the stock option expenses in accordance with accounting standards, estimating the impact on net profit over the years [17][18]. - The fair value of the stock options will be calculated using the Black-Scholes model, and the costs will be amortized over the vesting period [17][18].

Core Viewpoint - The announcement details the implementation of the 2024 Restricted Stock and Stock Option Incentive Plan, highlighting the conditions for the first exercise period and the approval process by the board and supervisory committee [1][2][3]. Group 1: Incentive Plan Approval and Implementation - The board and supervisory committee approved the 2024 Restricted Stock and Stock Option Incentive Plan during meetings held on July 24, 2025 [1]. - The plan includes a draft and management measures for the implementation of the incentive program, which were submitted for board review [2][3]. Group 2: Conditions for Exercising Stock Options - A total of 19 eligible participants can exercise stock options, with 1.3 million options available at an exercise price of 9.97 yuan per option [4][5]. - The exercise period starts on August 28, 2025, following the completion of the first waiting period [4][5]. Group 3: Performance Assessment and Compliance - The company must meet specific performance criteria, including a minimum revenue threshold for 2024, to validate the exercise of stock options [6][7]. - The individual performance assessment of participants is categorized into "qualified" and "unqualified," affecting their ability to exercise options [8]. Group 4: Monitoring and Legal Compliance - The supervisory committee confirmed that the performance results of the 19 eligible participants comply with legal and regulatory requirements [11][12]. - Legal opinions affirm that the necessary approvals and procedures for the exercise of options have been followed, ensuring compliance with relevant laws and regulations [12][13].

Core Viewpoint - Longbai Group reported a decline in revenue and net profit for the first half of 2025, primarily due to falling titanium dioxide prices and low industry demand [1][2]. Financial Performance - In H1 2025, Longbai Group achieved total revenue of 13.342 billion yuan, a year-on-year decrease of 3.35% - The net profit attributable to shareholders after deducting non-recurring items was 1.347 billion yuan, down 19.61% - In Q2 2025, revenue was 6.282 billion yuan, a decline of 3.5% year-on-year and 11.01% quarter-on-quarter - The net profit for Q2 was 688 million yuan, down 8.27% year-on-year [1][2]. Production and Sales - The company produced 682,200 tons of titanium dioxide in H1 2025, an increase of 5.02% year-on-year - Sales volume for titanium dioxide reached 612,000 tons, up 2.08% year-on-year - The average price of titanium dioxide in H1 2025 was 14,648.34 yuan per ton, a decrease of 9.87% year-on-year [2]. Market Conditions - The average price of titanium dioxide in Q2 2025 was 14,831 yuan per ton, down 9.79% year-on-year but up 2.53% quarter-on-quarter - As of August 18, 2025, the domestic average price of titanium dioxide fell to 13,274 yuan per ton, marking the lowest point of the year - The overall production of titanium dioxide in China for H1 2025 was 2.305 million tons, a slight decrease of 0.37% year-on-year [2][3]. Export Performance - In H1 2025, titanium dioxide exports reached 2.5166 million tons, a significant increase of 158.63% year-on-year - However, Q2 2025 exports were 415,600 tons, down 13.97% year-on-year and 17.05% quarter-on-quarter [2][3]. Shareholder Engagement - The company initiated a share repurchase plan in June 2025, having repurchased 1,564,600 shares by July 31, 2025, representing 0.0656% of total shares, with a total transaction amount of 25.48 million yuan - This move is aimed at enhancing shareholder value and reflects management's confidence in the company's long-term prospects [4]. Dividend Distribution - On June 10, 2025, the company completed its first-quarter dividend distribution, paying 5.00 yuan per 10 shares, totaling 1.186 billion yuan - This distribution aligns with the company's ongoing strategy to reward shareholders [5]. Earnings Forecast - Due to the downturn in the titanium dioxide industry, the company's revenue forecasts for 2025-2027 are adjusted to 27.582 billion, 29.885 billion, and 31.071 billion yuan respectively - Expected net profits for the same period are 2.684 billion, 3.603 billion, and 4.289 billion yuan, with corresponding EPS of 1.12, 1.51, and 1.80 yuan per share [6].

Core Viewpoint - The article emphasizes the importance of a well-designed equity structure in partnership entrepreneurship, highlighting that the era of solo entrepreneurship has passed and that the equity design directly impacts a company's future and fate [1]. Group 1: Equity Structure Design - When starting a partnership, it is crucial to determine equity ratios based on shareholders' funding, resources, and technical backgrounds [1]. - Designing a dynamic equity structure allows for adjustments in equity distribution as the company develops and shareholder contributions change [1]. - Many founders lose control of their companies as they grow; understanding how to maintain control is essential [1]. Group 2: Risk Management and Liability - The article discusses why some individuals are required to repay debts after a company's bankruptcy while others are not, emphasizing the need for a firewall to protect shareholders from joint liability and other risks [1]. Group 3: Training Program - The article promotes a training program titled "Equity Design and Partnership Implementation Practical 8-Day Experience Camp," aimed at helping participants master the key aspects of equity structure design and partnership implementation [1]. - The program includes two online live sessions with equity design experts, addressing practical challenges and blind spots in equity design [6]. - Participants will have the opportunity to win a free offline training spot valued at 3980 yuan through live session attendance [8]. Group 4: Schedule and Learning Outcomes - The training camp features a detailed schedule, including pre-study materials and daily live sessions covering various topics related to equity structure and partnership design [11]. - Participants will benefit from two live sessions, six days of video courses, and the chance to engage directly with experts, enhancing their understanding of practical equity design [12].

Company Performance - As of August 22, 2025, Fengcai Technology (688279) closed at 222.49 yuan, up 6.63% from the previous week's 208.65 yuan [1] - The stock reached a peak price of 230.86 yuan on August 22 and a low of 205.22 yuan on August 18 [1] - The current market capitalization is 25.346 billion yuan, ranking 58th out of 163 in the semiconductor sector and 724th out of 5,152 in the A-share market [1] Company Announcements - Fengcai Technology announced a series of important updates, including the results of the H-share special general meeting [2] - The company will undergo internal structural adjustments with key dates set: August 26, 2025, for important matters review; August 15, 2025, for the implementation of adjustments; and June 30, 2025, as another significant date [3] - A significant activity is planned for August 15, 2025, with details to be disclosed on August 27, 2025 [4] Financial Operations - Guotai Junan Securities has reviewed Fengcai Technology's plan to conduct foreign exchange hedging to mitigate currency fluctuation risks, with a funding limit of up to 1.5 billion yuan or equivalent foreign currency [5] - The hedging activities will include forward foreign exchange settlements, foreign exchange swaps, futures, and options, with a trading limit not exceeding the authorized amount at any point during the term [5] - The proposal for the foreign exchange hedging business has been approved by the board and will be submitted for shareholder approval [5] Shareholder Decisions - The 2025 equity incentive plan received overwhelming support, with 99.998% of A-share shareholders voting in favor and 97.3114% of H-share shareholders supporting the plan [6] - The total share capital as of August 15, 2025, is 113,919,380 shares, including 92,363,380 A-shares and 21,556,000 H-shares [6] - The company plans to issue 193,000 special A-shares [6]

Core Viewpoint - The company demonstrates resilience in a challenging OTC market, with a focus on growth in health consumer products and prescription drugs, while maintaining strong profitability and cash flow [1][2][3]. Group 1: Company Performance - In the first half of 2025, the company reported revenues of 2.14 billion yuan, a decrease of 6% year-on-year, while net profit attributable to shareholders increased by 6% to 520 million yuan [1]. - The second quarter of 2025 saw revenues of 960 million yuan, down 4% year-on-year, but net profit attributable to shareholders rose by 6% to 240 million yuan [1]. - The decline in revenue is primarily attributed to changes in OTC demand, but the company has optimized costs and expenses, leading to improved profitability [1]. Group 2: Industry Context - The pharmaceutical manufacturing industry in China faced a 1.2% decline in revenue and a 2.8% drop in profit in the first half of 2025 [2]. - OTC revenue for the company fell by 10% year-on-year to 1.55 billion yuan, while health consumer products grew by 17% to 230 million yuan, and prescription drug revenue increased by 7% to 360 million yuan [2]. Group 3: Profitability and Cash Flow - The gross margin for the first half of 2025 was 66.6%, a decrease of 2.4 percentage points year-on-year, mainly due to a lower proportion of high-margin OTC business [3]. - The company maintained a weighted average return on equity of 12.89%, an increase of 1.02 percentage points year-on-year, indicating sustained improvement in profitability [3]. - Operating cash flow net amount was 650 million yuan, while investment cash flow net amount was -330 million yuan, reflecting stable cash flow management [3]. Group 4: Dividend Policy - The company plans to distribute a cash dividend of 0.5 yuan per share, representing 60.78% of the net profit attributable to shareholders for the first half of 2025 [4]. - The company emphasizes high shareholder returns, maintaining a policy of two cash dividend distributions annually during the 14th Five-Year Plan period [4]. Group 5: Investment Outlook - The company maintains a profit forecast, expecting net profits attributable to shareholders of 897 million yuan, 1.015 billion yuan, and 1.145 billion yuan for 2025-2027, representing year-on-year growth of 14%, 13%, and 13% respectively [5]. - A target price of 29.96 yuan is set based on a 21x PE ratio for 2025, maintaining a "buy" rating [5].

Financial Performance - The company reported a total revenue of 5.296 billion yuan for the first half of 2025, representing a year-on-year increase of 31.31% [1] - The net profit attributable to shareholders reached 492 million yuan, up 28.07% year-on-year [1] - In Q2 2025, total revenue was 2.691 billion yuan, with a year-on-year growth of 26.66%, and net profit was 243 million yuan, increasing by 20.68% [1] Key Financial Ratios - Gross margin stood at 48.33%, a decrease of 0.79% compared to the previous year [1] - Net margin was 9.78%, down 2.85% year-on-year [1] - The ratio of selling, general, and administrative expenses to revenue was 31.72%, a decrease of 3.65% year-on-year [1] Accounts Receivable and Cash Flow - Accounts receivable amounted to 1.205 billion yuan, accounting for 173.23% of the net profit, indicating a significant receivables issue [2] - Operating cash flow per share increased by 77.62% to 0.58 yuan [1] Investment and Debt - The company’s interest-bearing debt rose to 2.084 billion yuan, an increase of 34.92% [1] - Cash and cash equivalents decreased by 60.88% to 1.532 billion yuan [1] Market Position and Growth Strategy - The company is focusing on high-potential product categories such as high-end dressings and surgical kits, aiming to establish a leading position in niche markets [7] - The domestic hospital business is expected to grow significantly, with strategies to enhance market share through competitive pricing and product promotion [8] Fund Management and Investor Interest - The company is held by a prominent fund manager, who has recently increased their stake, indicating strong investor confidence [2] - The largest fund holding the company is the "交银内需增长一年持有混合" fund, which has shown a significant increase in value over the past year [3]

Core Viewpoint -航亚科技's financial report for the first half of 2025 shows a revenue of 369 million yuan, an increase of 8.76% year-on-year, but a net profit attributable to shareholders decreased by 8.92% to 61.21 million yuan, primarily due to increased share-based payment expenses [3][4][8] Financial Performance - The company's revenue for the first half of 2025 was 369 million yuan, with a year-on-year growth of 8.76% [3] - The net profit attributable to shareholders was 61.21 million yuan, a decrease of 8.92% year-on-year [3] - The non-recurring net profit was 53.90 million yuan, down 18.35% year-on-year [3] - The increase in share-based payment expenses was the main reason for the decline in net profit [4][6] Expense Analysis - The company's operating expenses, referred to as "three fees," saw significant increases: sales expenses rose by 16.17%, management expenses by 40.12%, and financial expenses surged by 106.71% [4] - The increase in share-based payment expenses was a major contributor to the rise in sales and management expenses [4][6] Share-Based Payment Plan - The company implemented a restricted stock incentive plan in 2024, granting 5.5 million shares to incentivize management and align their interests with shareholders [5] - A high concentration of share grants was noted, with six core executives receiving 60% of the total shares allocated under the plan [6][7] Accounts Receivable Concerns - The company's accounts receivable reached 392 million yuan by the end of June 2025, exceeding its revenue for the first half of 2025 [8][9] - The accounts receivable as a percentage of revenue has increased significantly over the past three years, indicating a growing reliance on credit sales [8][9] - The company acknowledged the risks associated with high accounts receivable but noted that 95.45% of it was within one year, with clients being reputable aviation companies [8][10] Cash Flow Situation - Despite revenue growth, the net cash flow from operating activities decreased by 35.55% year-on-year, indicating potential liquidity issues [8][10]

Core Viewpoint - The company plans to repurchase shares through a centralized bidding process, with a total amount ranging from RMB 30 million to 60 million, aimed at employee stock ownership plans or equity incentives [1][2][4]. Summary by Sections Repurchase Plan Overview - The repurchase amount is set between RMB 30 million and 60 million [1][2]. - The funding source for the repurchase will be the company's own funds [1][5]. - The maximum repurchase price is capped at RMB 25 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [1][4]. - The repurchase will be conducted via centralized bidding [1][3]. - The duration for the repurchase is 12 months from the board's approval [1][3]. Purpose and Use of Repurchased Shares - The repurchased shares will be used for employee stock ownership plans or equity incentives [1][3][4]. - If the shares are not fully utilized for these purposes within three years, the company will follow the necessary procedures to cancel the unused shares and reduce registered capital accordingly [4][5]. Implementation and Conditions - The repurchase plan requires approval from at least two-thirds of the board members and does not need to be submitted to the shareholders' meeting [2][3]. - The estimated number of shares to be repurchased is between 120,000 and 240,000, representing 0.17% to 0.34% of the total share capital [2][4]. - The company will adjust the repurchase price if there are any capital changes, such as stock splits or dividends [4][5]. Financial Impact - The total amount for the repurchase represents approximately 1.10% of the company's total assets and 1.26% of the equity attributable to the parent company [5]. - The company asserts that the repurchase will not significantly impact its daily operations, financial status, research and development, profitability, or debt servicing capabilities [5][6]. Management and Compliance - The board has authorized the management to handle all matters related to the repurchase, including adjustments based on market conditions [7]. - There are no current plans for share reduction by directors, senior management, or major shareholders in the next three to six months [6][8].

北京市中伦（深圳）律师事务所 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 广东省深圳市福田区益田路 6003 号荣超中心 A 栋 8-10 层 邮编：518026 电话/Tel : +86 755 3325 6666 传真/Fax : +86 755 3320 6888/6889 www.zhonglun.com 关于兆易创新科技集团股份有限公司 第四个行权期行权条件及解除限售期解除限售条件 成就相关事项的 法律意见书 二〇二五年八月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 一、本所及本所经办律师根据《证券法》《律师事务所从事证券法律业 ...